Friends of FSH Research - Research News

Research: Research News

The pathophysiology of FSHD is finally becoming clear, but a great deal of uncertainty exists because of how variable the disease seems to be. Some progress has been made in determining relevant genetic factors. Perhaps most importantly, no treatments are available at this time, though a few potential treatments are currently being researched.

Read about the latest news and updates on FSHD Research.

Links to articles:

Platform development and candidate drug screening for FSHD Article update.
Lab Update A brief update by Joel Chamberlain on the RNAi she is using to destroy DUX4 messenger RNA.
Lab Update A brief update by Stephen Tapscott on current and future work.
DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy.
An update by Gregory Block for the work done on the Mechanism of Wnt Signaling in Facioscapulohumeral Muscular, funded by Friends of FSH Research (see Grants).
A summary by Seth Friedman for the work done on an MR Evaluation of Skeletal Muscles, funded by Friends of FSH Research (see Grants), and a proposal to further understanding of changes in skeletal muscle.
An update by Barbara Page on the work done for the first of a 2-year project titled Using model organisms to identify new therapies and understand the pathogenesis of FSHD, funded by Friends of FSH Research (see Grants for 2010).
The FSHD Atrophic Myotube Phenotype Is Caused by DUX4 Expression These results constitute a proof of concept for the development of therapeutic approaches for FSHD targeting DUX4 expression.
Decreased Proliferation Kinetics of Mouse Myoblasts Overexpressing FRG1 — Results from Brian Kennedy funding (see FRG1 Research Grant).
Summary of Paper in Molecular Therapy From Joel R. Chamberlain and Davide Gabellini.
FSHD Overview Initial Posting: March 8, 1999; Last Update: July 9, 2009.
Incomplete Suppression of a Retrotransposed Gene An international research consortium shows that FSHD muscle nuclei are poised for expression of the toxic DUX4 protein.
Dr. Rabi Tawil on the Challenges of Unraveling the Genetics of FSHD
Manipulating Muscle Stem Cells to Treat Muscular Dystrophy Dr. Pier Lorenzo Puri, associate professor in the Sanford Children’s Health Research Center at Sanford-Burnham and colleagues are figuring out ways to keep the muscle stem cell pool fresh and ready to regenerate injured or diseased muscle.
An international collaboration identifies a region of DNA necessary for FSHD and focuses attention on DUX4 as the cause of muscle deterioration
$6.3 M Grant for FSH Research The Pathogenesis of FSHD
Sensing a Breakthrough: Fields Center Collaboration
Department of Clinical Physiology of the University Hospital of Montpellier, France - Clinical Study
Scientists develop new way to grow adult stem cells in culture
FSH Grant Awarded to UW Researcher
FSHD: The Most Prevalent Form of Muscular Dystrophy
September 2009: Myopathic Phenotype of Mouse DUX, an ORF within Conserved FSHD-Related Repeats
August 2009: Research Updates
Common Epigenetic Changes of D4Z4 in Contraction-dependent and Contraction-independent FSHD
June 2009: The Beginnings of something new in FSHD Research?
RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of FSHD
Dr. Michael Kyba: Evaluating the stem cell hypothesis for FSHD

Our Donors

Please take a moment to view our generous donors.

Connect With Us